Hormones & metabolism Mitochondrial-derived peptide
MOTS-c
Regulatory status
Status at a glance
503A compounding status
Advisory committee voted to include
FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted in favor of adding this substance to the 503A bulks list. PCAC votes are non-binding recommendations; FDA and HHS make the final decision, and the substance is not on the bulks list unless FDA adds it.
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- On the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
MOTS-c is a small peptide encoded within the mitochondria, studied as an "exercise mimetic" for metabolic health, and sold on the "research peptide" market. Its evidence is preclinical and observational, with no completed trials testing the administered peptide in people. As of 2026 it is not FDA-approved, though a 2026 FDA advisory committee gave a non-binding favorable vote toward allowing it to be compounded.
At a glance
- FDA status
- Non-FDA-approved peptide sold in the wellness/gray market
- What it is
- Naturally occurring mitochondrial-derived peptide studied in metabolism and exercise
- Research
- Animal and observational; no completed interventional human trials of the given peptide
- Compounding
- A 2026 FDA advisory vote was favorable but non-binding; not yet compoundable on that basis
- Evidence strength
- Low research
Summary
MOTS-c is a mitochondrial peptide studied as an exercise mimetic. See what preclinical research shows, why human evidence is lacking, and its FDA status.
What is MOTS-c?
MOTS-c is a naturally occurring 16-amino acid peptide encoded within the mitochondria, the cell's energy structures. It has drawn research interest as a possible "exercise mimetic" for metabolic health. It is sold through wellness and "research peptide" channels, and it is not an approved medicine.
How does it work?
MOTS-c is proposed to move into the cell nucleus under metabolic stress and influence genes that regulate metabolism, including the AMPK energy-sensing pathway, improving muscle glucose handling and insulin sensitivity. Its blood levels reportedly decline with age and rise after intense exercise. In mice, MOTS-c improved exercise capacity and metabolic markers. These are cell and animal findings. This describes the proposed mechanism, separate from demonstrated benefit in people.
Is it FDA-approved?
Safety note
Status: Non-FDA-approved peptide sold in the wellness/gray market
Category: Wellness and performance · Primary body area: Hormones & metabolism
No. MOTS-c is not approved by the FDA. In July 2026 the FDA's Pharmacy Compounding Advisory Committee gave MOTS-c a non-binding favorable vote toward the 503A compounding list. Because that vote is only a recommendation and the FDA has not completed rulemaking, MOTS-c is not currently on the list and cannot be legally compounded by U.S. pharmacies on that basis.
What does the research show?
Editor’s note
Evidence strength: Low research (1 human · 1 animal/cell studies)
The mechanism is interesting but human data are observational only, with no trials of the administered peptide establishing a benefit.
The evidence is largely preclinical:
| Study type | What it shows |
|---|---|
| Cell and rodent studies | The source of the metabolic and exercise effects, according to PubMed, summarized in reviews of its therapeutic potential and of mitochondrial peptides and exercise |
| Human studies | Mostly observational rather than interventional, showing that circulating MOTS-c rises after exercise |
| Trials of administered MOTS-c | None completed for any metabolic or performance use |
Its marketed benefit is therefore unproven in people.
Sources: reviews of MOTS-c and mitochondrial-derived peptides (Frontiers in Endocrinology, 2023, DOI: 10.3389/fendo.2023.1120533; Biochimica et Biophysica Acta General Subjects, 2021, DOI: 10.1016/j.bbagen.2021.130011), indexed on PubMed; and reporting on the July 2026 FDA advisory committee vote. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.
Registered human trials
1 registered human trial on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
Compare every peptide’s status in the peptide regulatory status database
More for Hormones & metabolism
View all hormones & metabolism peptides →- FDA-approved Hormones & metabolism
Albiglutide
Albiglutide is a once-weekly GLP-1 receptor agonist made by fusing GLP-1 analog chains to human albumin, approved for type 2 diabetes in 2014 as Tanzeum. It had a somewhat weaker effect on gastric emptying and appetite than some other GLP-1 drugs but showed a cardiovascular benefit in the HARMONY OUTCOMES trial. Despite that, GSK withdrew it from the market in 2018 for commercial reasons, so it remains FDA-approved but is no longer available.
- Not FDA-approved Hormones & metabolism
Compounded-Tesamorelin
Tesamorelin is an FDA-approved growth-hormone-releasing peptide, sold as Egrifta, for excess abdominal fat in HIV-associated lipodystrophy. In a randomized trial of 404 people with HIV (Falutz 2010), visceral fat fell 10.9% on tesamorelin versus 0.6% on placebo over 6 months. Its off-label use for body composition and anti-aging in people without HIV is not an approved indication and lacks dedicated trials. It is banned in sport.
- FDA-approved Hormones & metabolism
Corticotropin
ACTH
Corticotropin (adrenocorticotropic hormone, or ACTH; sold as Acthar Gel and Purified Cortrophin Gel) is a hormone preparation that stimulates the adrenal glands to make their own steroids and also acts directly on immune cells. It is one of the oldest biologic medicines, used today for conditions ranging from infantile spasms to multiple sclerosis relapses. It has been FDA-approved in the U.S. since 1952 and is given as a long-acting injection.
- FDA-approved Hormones & metabolism
Cosyntropin
Cosyntropin (sold as Cortrosyn) is a synthetic fragment of adrenocorticotropic hormone used as a diagnostic agent to test whether the adrenal glands are working. A dose is given and the resulting rise in cortisol shows how well the adrenals respond. It has long been FDA-approved in the U.S. and is given as a single injection during the test.
- FDA-approved Hormones & metabolism
Dulaglutide
Dulaglutide is a once-weekly GLP-1 receptor agonist built by fusing two GLP-1 analog chains to an antibody fragment, which extends its action to about five days. It was approved for type 2 diabetes in 2014 and gained a cardiovascular indication in 2020 after the REWIND trial showed a roughly 12% reduction in major cardiovascular events. It remains on the market as Trulicity.
- In clinical trials Hormones & metabolism
Efpeglenatide
Efpeglenatide is an investigational long-acting GLP-1 receptor agonist, originally developed by Hanmi Pharmaceutical, given as a once-weekly injection for type 2 diabetes and cardiovascular risk. In a large Phase 3 outcomes trial it reduced major cardiovascular events in people with type 2 diabetes. As of 2026, it has not reached approval in major markets.